Atherosclerotic Cardiovascular Disease Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts

DelveInsight's "Atherosclerotic Cardiovascular Disease (ASCVD) Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Atherosclerotic Cardiovascular Disease, historical and forecasted epidemiology as well as the Atherosclerotic Cardiovascular Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Atherosclerotic Cardiovascular Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atherosclerotic Cardiovascular Disease Market Forecast
https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Atherosclerotic Cardiovascular Disease Market Report:
• The Atherosclerotic Cardiovascular Disease market size was valued approximately USD 23,370 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In September 2025, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to include the cardiovascular benefits observed in the SOUL trial. The Phase 3b SOUL study assessed the impact of Rybelsus® on cardiovascular outcomes in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). With this approval, Rybelsus® becomes the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in the EU for type 2 diabetes with demonstrated cardiovascular benefits, mimicking a natural hormone that regulates blood sugar, appetite, and digestion.
• In December 2024, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage biopharmaceutical company focused on developing oral, non-statin treatments for patients at risk of cardiovascular disease (CVD) with elevated LDL cholesterol, announced promising topline results from its Phase 3 BROADWAY clinical trial (NCT05142722). The trial assessed obicetrapib in adult patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL cholesterol levels remain inadequately controlled despite being on the maximum tolerated lipid-lowering therapy.
• In 2023, the United States held the largest share of the ASCVD market, accounting for approximately 52% of the total market size across the 7MM. This was notably higher compared to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Within the EU countries, Germany recorded the largest market size for ASCVD, reaching approximately USD 2,275 million in 2023. In contrast, the UK had the smallest market size, at around USD 1,325 million during the same year.
• In 2023, Japan's market size for ASCVD was approximately USD 3,058 million.
• According to DelveInsight's analysis, the total diagnosed prevalent cases of Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM were approximately 55.7 million in 2023.
• In 2023, the United States recorded the highest number of diagnosed prevalent cases of ASCVD, totaling 26 million, with projections indicating future growth.
• In 2023, Germany reported the highest number of diagnosed prevalent ASCVD cases among European countries, with approximately 5 million cases, followed by France at around 4 million. In contrast, Spain had the lowest diagnosed prevalence, with 3 million cases.
• In 2023, Japan recorded approximately 8 million diagnosed prevalent cases of ASCVD, representing around 15% of the total cases in the 7MM.
• Analysis reveals that in 2023, across the EU4 and the UK, males were more impacted by ASCVD than females, with around 12 million cases in males compared to 8 million in females.
• The diagnosed prevalent population of ASCVD in Japan was categorized into three age groups: 18-44 years, 45-64 years, and 65+ years. In 2023, the 45-64-year age group had the highest number of cases, approximately 5,480 thousand, followed by the 18-44-year group with around 1,645 thousand cases, and the 65+ year group with roughly 1,100 thousand cases.
• Key Atherosclerotic Cardiovascular Disease Companies: Novartis, Regeneron Pharmaceuticals, Sanofi, Amgen, Novo Nordisk A/S, Ionis Pharmaceuticals, NewAmsterdam Pharma, ResverlogixCorp, LIB Therapeutics, Merck Sharp & Dohme LLC, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
• Key Atherosclerotic Cardiovascular Disease Therapies: LEQVIO (inclisiran), PRALUENT (alirocumab), Olpasiran, Ziltivekimab, Olezarsen, Obicetrapib(TA-8995), Apabetalone, LIB003 (Lerodalcibep), CSL112: CSL Behring, TQJ230 (pelacarsen), MK-0616, Inclisiran, Ertugliflozin, Tetrahydrobiopterin, MEDI6570, GFH312, and others
• The Atherosclerotic Cardiovascular Disease epidemiology based on gender analyzed that men bear a greater burden than women regarding Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM
• The Atherosclerotic Cardiovascular Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atherosclerotic Cardiovascular Disease pipeline products will significantly revolutionize the Atherosclerotic Cardiovascular Disease market dynamics.

Atherosclerotic Cardiovascular Disease Overview
Atherosclerotic Cardiovascular Disease (ASCVD) is a condition where the arteries become narrowed and hardened due to the buildup of plaque, which consists of fatty deposits, cholesterol, and other substances. This process, known as atherosclerosis, can restrict blood flow to the heart, brain, and other parts of the body, increasing the risk of heart attacks, strokes, and peripheral artery disease. Common risk factors for ASCVD include high blood pressure, high cholesterol, smoking, diabetes, and a sedentary lifestyle. Management often involves lifestyle changes, medications to control risk factors, and, in some cases, surgical interventions to improve blood flow.

Get a Free sample for the Atherosclerotic Cardiovascular Disease Market Report:
https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atherosclerotic Cardiovascular Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Atherosclerotic Cardiovascular Disease Epidemiology Segmentation:
The Atherosclerotic Cardiovascular Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Atherosclerotic Cardiovascular Disease
• Prevalent Cases of Atherosclerotic Cardiovascular Disease by severity
• Gender-specific Prevalence of Atherosclerotic Cardiovascular Disease
• Diagnosed Cases of Episodic and Chronic Atherosclerotic Cardiovascular Disease

Download the report to understand which factors are driving Atherosclerotic Cardiovascular Disease epidemiology trends @ Atherosclerotic Cardiovascular Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atherosclerotic Cardiovascular Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atherosclerotic Cardiovascular Disease market or expected to get launched during the study period. The analysis covers Atherosclerotic Cardiovascular Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Atherosclerotic Cardiovascular Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Atherosclerotic Cardiovascular Disease Therapies and Key Companies
• LEQVIO (inclisiran): Novartis Pharmaceuticals Corporation
• PRALUENT (alirocumab): Regeneron Pharmaceuticals/Sanofi
• Olpasiran: Amgen
• Ziltivekimab: Novo Nordisk A/S
• Olezarsen: Ionis Pharmaceuticals
• Obicetrapib(TA-8995): NewAmsterdam Pharma
• Apabetalone: ResverlogixCorp
• LIB003 (Lerodalcibep): LIB Therapeutics
• CSL112: CSL Behring
• TQJ230 (pelacarsen): Novartis Pharmaceuticals
• MK-0616: Merck Sharp & Dohme LLC
• Inclisiran: Novartis Pharmaceuticals
• Ertugliflozin: Merck Sharp & Dohme LLC
• Tetrahydrobiopterin: BioMarin Pharmaceutical
• MEDI6570: AstraZeneca
• GFH312: Zhejiang Genfleet Therapeutics Co., Ltd.

Discover more about therapies set to grab major Atherosclerotic Cardiovascular Disease market share @ Atherosclerotic Cardiovascular Disease Treatment Market
https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atherosclerotic Cardiovascular Disease Market Strengths
• Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in Atherosclerotic Cardiovascular Disease (ASCVD).

Atherosclerotic Cardiovascular Disease Market Opportunities
• The lack of FDA-approved treatments for lowering Lp(a)presents an exciting opportunity for focused research on developing precise therapies in the realm of ASCVD

Scope of the Atherosclerotic Cardiovascular Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Atherosclerotic Cardiovascular Disease Companies: Novartis, Regeneron Pharmaceuticals, Sanofi, Amgen, Novo Nordisk A/S, Ionis Pharmaceuticals, NewAmsterdam Pharma, ResverlogixCorp, LIB Therapeutics, Merck Sharp & Dohme LLC, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
• Key Atherosclerotic Cardiovascular Disease Therapies: LEQVIO (inclisiran), PRALUENT (alirocumab), Olpasiran, Ziltivekimab, Olezarsen, Obicetrapib(TA-8995), Apabetalone, LIB003 (Lerodalcibep), CSL112: CSL Behring, TQJ230 (pelacarsen), MK-0616, Inclisiran, Ertugliflozin, Tetrahydrobiopterin, MEDI6570, GFH312, and others
• Atherosclerotic Cardiovascular Disease Therapeutic Assessment: Atherosclerotic Cardiovascular Disease current marketed and Atherosclerotic Cardiovascular Disease emerging therapies
• Atherosclerotic Cardiovascular Disease Market Dynamics: Atherosclerotic Cardiovascular Disease market drivers and Atherosclerotic Cardiovascular Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Atherosclerotic Cardiovascular Disease Unmet Needs, KOL's views, Analyst's views, Atherosclerotic Cardiovascular Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.